converting between glp-1 agonists PDF] Switching Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance Approaches for half-life extension of

AtenciN

Back Weir, GC, Mojsov, S, Hendrick, GK, Habener, JE (March 1989) 'Glucagonlike peptide I (7-37) actions on endocrine pancreas', Diabetes , 38, 338-42

After discontinuing its internal GLP-1 in May of 2025 for causing liver issues, Pfizer won a bidding war against seven other companies for Metsera, which is developing a variety of incretin assets, paying $10 billion in one of 2025s largest M&A deals

2024 doi: 10.1016/j.cgh.2024.03.013

The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language

Optum Rx has introduced a host of tools at the formulary and benefit design levels, to ensure GLP-1 drugs are used responsibly